PHP
MBX

Parkman Healthcare Partners’s MBX Biosciences MBX Stock Holding History

Parkman Healthcare Partners’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$23.9M Sell
800,037
-85,602
-10% -$2.91M 2.46% 13
2025
Q4 		$27.9M Buy
885,639
+112,335
+15% +$2.73M 2.66% 8
2025
Q3 		$13.5M Sell
773,304
-98,629
-11% -$1.32M 1.41% 22
2025
Q2 		$9.95M Buy
871,933
+543,610
+166% +$5.54M 1.14% 29
2025
Q1 		$2.42M Buy
328,323
+158,323
+93% +$1.67M 0.29% 71
2024
Q4 		$3.13M Buy
+170,000
New +$3.62M 0.42% 60

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Parkman Healthcare Partners's MBX Position: Q1 2026 in Review

Parkman Healthcare Partners reduced its MBX Biosciences (MBX) stake by 9.7% in Q1 2026, selling an estimated $2.91M and leaving 800,037 shares worth $23.9M. The position accounts for 2.46% of the portfolio, ranked #13.

Parkman Healthcare Partners first reported a position in MBX in Q4 2024 and has held it in 6 quarters since. The position peaked at $27.9M in Q4 2025. 157 funds tracked by Wall St. Rank hold MBX as of Q1 2026.

  • Parkman Healthcare Partners held 800,037 shares of MBX Biosciences worth $23.9M as of Q1 2026.
  • Parkman Healthcare Partners sold 85,602 MBX Biosciences shares in Q1 2026, an estimated $2.91M.
  • MBX Biosciences made up 2.46% of Parkman Healthcare Partners's portfolio in Q1 2026, its #13 holding.
  • Parkman Healthcare Partners first reported a position in MBX Biosciences in Q4 2024 and has held it in 6 quarters since.
  • Parkman Healthcare Partners's MBX Biosciences position peaked at $27.9M in Q4 2025.
  • 157 funds tracked by Wall St. Rank held MBX Biosciences as of Q1 2026.

Based on Parkman Healthcare Partners's 13F filing for Q1 2026, filed 15 May 2026.